RAAS antagonist therapy for prevention of atrial fibrillation in hypertension / 中华全科医师杂志
Chinese Journal of General Practitioners
;
(6): 81-84, 2019.
Article
Dans Chinois
| WPRIM
| ID: wpr-734849
ABSTRACT
Hypertension is the most common and controlable risk factor of atrial fibrillation (AF).Resin-angiotensin-aldosterone system (RAAS) antagonist therapy may reduce atrial remodeling and hold promise as “upstream” therapy for AF,especially for the patients with left ventricular hypertrophy and left ventricular dysfunction.The RAAS antagonist therapy for prevention of AF in hypertensive patients needs to be further explored in large scale randomized studies.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Type d'étude:
Essai clinique contrôlé
/
Facteurs de risque
langue:
Chinois
Texte intégral:
Chinese Journal of General Practitioners
Année:
2019
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS